Your browser doesn't support javascript.
loading
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data.
Magliano, Dianna J; Chen, Lei; Carstensen, Bendix; Gregg, Edward W; Pavkov, Meda E; Salim, Agus; Andes, Linda J; Balicer, Ran; Baviera, Marta; Chan, Juliana C N; Cheng, Yiling J; Gardiner, Helene; Gulseth, Hanne L; Gurevicius, Romualdas; Ha, Kyoung Hwa; Jermendy, György; Kim, Dae Jung; Kiss, Zoltán; Leventer-Roberts, Maya; Lin, Chun-Yi; Luk, Andrea O Y; Ma, Stefan; Mata-Cases, Manel; Mauricio, Didac; Nichols, Gregory A; Pildava, Santa; Porath, Avi; Read, Stephanie H; Robitaille, Cynthia; Roncaglioni, Maria Carla; Lopez-Doriga Ruiz, Paz; Wang, Kang-Ling; Wild, Sarah H; Yekutiel, Naama; Shaw, Jonathan E.
Afiliação
  • Magliano DJ; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Electronic address: Dianna.magliano@baker.edu.au.
  • Chen L; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
  • Carstensen B; Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Gregg EW; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Pavkov ME; Division of Diabetes Translation, Centers for Diseases Control and Prevention, Atlanta, GA, USA.
  • Salim A; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Andes LJ; Division of Diabetes Translation, Centers for Diseases Control and Prevention, Atlanta, GA, USA.
  • Balicer R; Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Baviera M; Laboratory of Cardiovascular Prevention, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.
  • Chan JCN; Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, China.
  • Cheng YJ; Division of Diabetes Translation, Centers for Diseases Control and Prevention, Atlanta, GA, USA.
  • Gardiner H; Centre for Surveillance and Applied Research, Public Health Agency of Canada, Ottawa, ON, Canada.
  • Gulseth HL; Department for Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
  • Gurevicius R; Center of Health Information, Institute of Hygiene, Vilnius, Lithuania; Faculty of Public Governance and Business, Mykolas Romeris University, Vilnius, Lithuania.
  • Ha KH; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
  • Jermendy G; 3rd Medical Department, Bajcsy-Zsilinszky Hospital, Budapest, Hungary.
  • Kim DJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
  • Kiss Z; 2nd Department of Medicine and Nephrological Center, Medical Faculty, University of Pécs, Pécs, Hungary.
  • Leventer-Roberts M; Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel; Departments of Pediatrics and Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lin CY; General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Luk AOY; Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, China.
  • Ma S; Epidemiology and Disease Control Division, Public Health Group, Ministry of Health, Singapore.
  • Mata-Cases M; CIBER of Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Institut Català de la Salut, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.
  • Mauricio D; CIBER of Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Institut Català de la Salut, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain; Departme
  • Nichols GA; Science Programs Department, Kaiser Permanente Center for Health Research, Portland, OR, USA.
  • Pildava S; Research and Health Statistics Department, Centre for Disease Prevention and Control, Riga, Latvia.
  • Porath A; Research Institute, Maccabi Healthcare Services, Tel Aviv, Israel; Faculty of Health, Ben Gurion University, Beer-Sheva, Israel.
  • Read SH; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Robitaille C; Centre for Surveillance and Applied Research, Public Health Agency of Canada, Ottawa, ON, Canada.
  • Roncaglioni MC; Laboratory of Cardiovascular Prevention, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.
  • Lopez-Doriga Ruiz P; Department for Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
  • Wang KL; General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Wild SH; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Yekutiel N; Research Institute, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Shaw JE; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; School of Life Sciences, Latrobe University, Melbourne, VIC, Australia.
Lancet Diabetes Endocrinol ; 10(2): 112-119, 2022 02.
Article em En | MEDLINE | ID: mdl-35026157
BACKGROUND: Population-level trends in mortality among people with diabetes are inadequately described. We aimed to examine the magnitude and trends in excess all-cause mortality in people with diabetes. METHODS: In this retrospective, multicountry analysis, we collected aggregate data from 19 data sources in 16 high-income countries or jurisdictions (in six data sources in Asia, eight in Europe, one from Australia, and four from North America) for the period from Jan 1, 1995, to Dec 31, 2016, (or a subset of this period) on all-cause mortality in people with diagnosed total or type 2 diabetes. We collected data from administrative sources, health insurance records, registries, and a health survey. We estimated excess mortality using the standardised mortality ratio (SMR). FINDINGS: In our dataset, there were approximately 21 million deaths during 0·5 billion person-years of follow-up among people with diagnosed diabetes. 17 of 19 data sources showed decreases in the age-standardised and sex-standardised mortality in people with diabetes, among which the annual percentage change in mortality ranged from -0·5% (95% CI -0·7 to -0·3) in Hungary to -4·2% (-4·3 to -4·1) in Hong Kong. The largest decreases in mortality were observed in east and southeast Asia, with a change of -4·2% (95% CI -4·3 to -4·1) in Hong Kong, -4·0% (-4·8 to -3·2) in South Korea, -3·5% (-4·0 to -3·0) in Taiwan, and -3·6% (-4·2 to -2·9) in Singapore. The annual estimated change in SMR between people with and without diabetes ranged from -3·0% (95% CI -3·0 to -2·9; US Medicare) to 1·6% (1·4 to 1·7; Lombardy, Italy). Among the 17 data sources with decreasing mortality among people with diabetes, we found a significant SMR increase in five data sources, no significant SMR change in four data sources, and a significant SMR decrease in eight data sources. INTERPRETATION: All-cause mortality in diabetes has decreased in most of the high-income countries we assessed. In eight of 19 data sources analysed, mortality decreased more rapidly in people with diabetes than in those without diabetes. Further longevity gains will require continued improvement in prevention and management of diabetes. FUNDING: US Centers for Disease Control and Prevention, Diabetes Australia Research Program, and Victoria State Government Operational Infrastructure Support Program.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Idioma: En Ano de publicação: 2022 Tipo de documento: Article